Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHORE: Ranibizumab Dosing Regimens for Macular Edema Following RVO
NCT01277302Phase 4Completed
- Sponsor
- Genentech
- Start
- Feb 2011
- Primary completion
- Oct 2012
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of ranibizumab in macular edema, sponsored by Genentech. Started Feb 2011; status: completed.
02
Drugs
ranibizumab
03
Conditions
macular edema
Beyond the preview
Go deeper on NCT01277302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01277302.